Pd-Catalyzed Nucleophilic Fluorination of Aryl Bromides
摘要:
On the basis of mechanism-driven reaction design, a Pd-catalyzed nucleophilic fluorination of aryl bromides and iodides has been developed. The method exhibits a broad substrate scope, especially with respect to nitrogen-containing heteroaryl bromides, and proceeds with minimal formation of the corresponding reduction products. A facilitated ligand modification process was shown to be critical to the success of the reaction.
This invention provides compounds of Formula (I),
1
where A″, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
[EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2014139325A1
公开(公告)日:2014-09-18
Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
Hypervalent Iodine(III)-Catalyzed Balz-Schiemann Fluorination under Mild Conditions
作者:Bo Xing、Chuanfa Ni、Jinbo Hu
DOI:10.1002/anie.201802466
日期:2018.7.26
An unprecedented hypervalentiodine(III) catalyzed Balz–Schiemann reaction is described. In the presence of a hypervalentiodine compound, the fluorination reaction proceeds under mild conditions (25–60 °C), and features a wide substrate scope and good functional‐group compatibility.
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
申请人:American Home Products Corporation
公开号:US20020026052A1
公开(公告)日:2002-02-28
This invention provides compounds of Formula (I), having the structure
1
where T, Z, X, A, R
1
, R
2a
, R
2b
, R
2c
, R
3
, R
4
, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.
Compounds of general formula I:
and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.